'Alpha L-Iduronidase (IDUA or EC 188.8.131.52) - Pipeline Review, H2 2017' outlays comprehensive information on the Alpha L-Iduronidase (IDUA or EC 184.108.40.206) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
Alpha L-Iduronidase (IDUA or EC 220.127.116.11) - Alpha L-iduronidase is an enzyme encoded by IDUA gene. It hydrolyzes the terminal alpha-L-iduronic acid residues of two glycosaminoglycans, dermatan sulfate and heparan sulfate.
Mutations in this gene that result in enzymatic deficiency lead to the autosomal recessive disease mucopolysaccharidosis type I (MPS I).
Complete Report Available at www.themarketreports.com/report/al…ne-review-h2-2017
- The report provides a snapshot of the global therapeutic landscape for Alpha L-Iduronidase (IDUA or EC 18.104.22.168)
- The report reviews Alpha L-Iduronidase (IDUA or EC 22.214.171.124) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Alpha L-Iduronidase (IDUA or EC 126.96.36.199) targeted therapeutics and enlists all their major and minor projects
Access this Report at www.themarketreports.com/report/941670
Reasons To Access
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Alpha L-Iduronidase (IDUA or EC 188.8.131.52)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Inquire About this Report at www.themarketreports.com/report/ask-your-query/941670
Category: Market Research Publishers and RetailersCompany about: The Market Reports aims to provide the best industry and market reports to a seeker. We are looking forward to a place where we are the one stop destination for all the report seekers irrespective of any country, category, domain, etc. We are always open on call and email (24*7) to your queries and very clean with the business methodology. Since we are dealing with so many Publishers, we can actually give you what suits best in accordance to your requirements.
For more information: